Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes
Public ClinicalTrials.gov record NCT07797036. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes: An Effectiveness-Implementation Hybrid Type 1 Randomized Trial
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an effectiveness-implementation Hybrid Type 1 study using a randomized clinical trial design to evaluate the effectiveness and potential real-world integration of immediate postpartum semaglutide following a pregnancy complicated by gestational diabetes mellitus (GDM). A total of 226 postpartum individuals with recent GDM will be randomized 1:1 to semaglutide or standard postpartum care for a 6-month active treatment phase. The primary effectiveness outcome, development of metabolic syndrome, will be assessed at 6 months postpartum. Participants will subsequently enter a 6-month maintenance phase, during which semaglutide continuation, discontinuation, or initiation will reflect patient preferences, clinical decision-making, medication access, and insurance coverage.
Study identification
- NCT ID
- NCT07797036
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 226 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2027
- Primary completion
- Aug 31, 2030
- Completion
- Dec 30, 2030
- Last update posted
- Aug 31, 2026
2027 – 2030
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UMass Memorial | Worcester | Massachusetts | 01605 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Gestational Diabetes Mellitus (GDM) trials
Other public records listing Gestational Diabetes Mellitus (GDM). Sorted by last update posted; newest first. Not a recommendation.
- NCT07565727: Cardiometabolic Disease and Substrate Metabolism Recruiting
- NCT07446205: Poi for Mama: a Pilot to Improve Maternal Microbiome and Gestational Diabetes Risk Recruiting
- NCT07176793: Pregnancy and Postpartum Breastfeeding Support for Patients With Gestational Diabetes Recruiting
- NCT06988306: Lifestyle Interventions to Prevent Diabetes in U.S. Home Visiting Programs Recruiting
- NCT06858787: Validating CGM for GDM Recruiting
- NCT06911372: The Impact of Gestational Diabetes Mellitus on Cerebral Blood Flow and Cerebrovascular Function After Pregnancy Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07797036, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 31, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07797036 live on ClinicalTrials.gov.